ScripGSK intends to file for US approval of the oral carbapenem antibiotic tebipenem-HBr to treat complicated urinary tract infections (cUTI) during the second half of 2025, three years after Spero Therape
ScripArcturus Therapeutics and licensing partner CSL have got approval in the EU for Kostaive, a self-amplifying mRNA (sa-mRNA) vaccine that the firms hope will become a major product in the COVID-19 space
In VivoPharmaceutical companies have a variety of strategic options available to them to restock pipelines and ensure continued innovation. In terms of external innovation, in-licensing assets from other com
Pink SheetA misinformation dispute in Japan over Arcturus Therapeutics' COVID-19 vaccine Kostaive (ARCT-154) saw an unprecedented twist in December, when local distributor Meiji Seika Pharma decided to pursue